CARDAX, INC. (OTCMKTS:CDXI) Files An 8-K Regulation FD Disclosure
ITEM 7.01 REGULATION FD DISCLOSURE.
Cardax, Inc. (the Company) announced today that ZanthoSyn, the
Companys first commercial product, will be available in all GNC
stores in Hawaii.
In accordance with General Instruction B.2 of Form 8-K, the
information set forth herein and in the exhibit hereto are deemed
to be furnished and shall not be deemed to be filed for purposes
of the Exchange Act. The information set forth in Item 7.01 of
this Current Report on Form 8-K shall not be deemed an admission
as to the materiality of any information in this Current Report
on Form 8-K that is required to be disclosed solely to satisfy
the requirements of Regulation FD.
Safe Harbor
This release may contain certain forward-looking statements
regarding our prospective performance and strategies within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as
amended. We intend such forward-looking statements to be covered
by the safe harbor provisions for forward-looking statements
contained in the Private Securities Litigation Reform Act of
1995, and are including this statement for purposes of said safe
harbor provisions. Forward-looking statements, which are based on
certain assumptions and describe future plans, strategies, and
expectations of our company, are generally identified by use of
words anticipate, believe, estimate, expect, intend, plan,
project, seek, strive, try, or future or conditional verbs such
as could, may, should, will, would, or similar expressions. Our
ability to predict results or the actual effects of our plans or
strategies is inherently uncertain. Accordingly, actual results
may differ materially from anticipated results. Some of the
factors that could cause our actual results to differ from our
expectations or beliefs include, without limitation, the risks
discussed from time to time in our filings with the Securities
and Exchange Commission. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this release. Except as required by applicable law
or regulation, we undertake no obligation to update these
forward-looking statements to reflect events or circumstances
that occur after the date on which such statements were made.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
| Exhibit No. | Description | |
| 99.1 | Press Release dated January 25, 2017 (furnished herewith) |
About CARDAX, INC. (OTCMKTS:CDXI)
Cardax, Inc. is a life sciences company. The Company develops consumer health and pharmaceutical technologies. The Company is engaged in developing and commercializing anti-inflammatory dietary supplements and drugs. The Company offers ZanthoSyn, a product to help consumers address their inflammatory health. ZanthoSyn is an astaxanthin dietary supplement distributed by the Company. ZanthoSyn features synthetic astaxanthin. Astaxanthin is an ingredient with anti-inflammatory activity that supports joint health, cardiovascular health, metabolic health and liver health. As of December 31, 2015, the Company had two other anti-inflammatory programs with application in various markets, including zeaxanthin esters for macular degeneration and hepatic disease, and lycophyll esters for prostate disease. CARDAX, INC. (OTCMKTS:CDXI) Recent Trading Information
CARDAX, INC. (OTCMKTS:CDXI) closed its last trading session 00.0000 at 0.0900 with 20,000 shares trading hands.